Study wrapper · #769
Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.
Editor's note
This systematic review and meta-analysis (eight studies, one randomised and seven observational, 323,439 patients) compared tirzepatide with GLP-1 receptor agonists for cardiovascular outcomes in adults with overweight or obesity. Researchers reported that tirzepatide was not associated with a statistically significant reduction in major adverse cardiovascular events versus GLP-1 RAs (HR 0.85, 95% CI 0.70-1.04), with very high heterogeneity (I-squared 90.4%). Estimates leaned in tirzepatide's favour for all-cause and cardiovascular mortality but crossed or touched the line of no difference. The evidence base is dominated by observational studies, so confounding limits causal reading, and the wide heterogeneity signals the studies are not measuring the same thing. The honest takeaway: no confirmed cardiovascular advantage over GLP-1 RAs yet; dedicated randomised outcome trials are needed.
Plain-language abstract
Researchers combined eight earlier studies (one randomised trial and seven real-world studies, together over 323,000 people with overweight or obesity) to see whether tirzepatide lowers the risk of major heart problems more than older GLP-1 medicines. Pooling the results, tirzepatide was not clearly better: the difference in major heart events could have been due to chance. The numbers pointed slightly in tirzepatide's favour for death from any cause and heart-related death, but not strongly enough to be certain. The studies disagreed with each other a great deal, and most were observational rather than controlled trials, which makes firm conclusions hard. The authors say dedicated randomised trials are needed to settle whether tirzepatide protects the heart better than other options.